Somewhat Positive Press Coverage Somewhat Unlikely to Impact Compugen (CGEN) Share Price
Media stories about Compugen (NASDAQ:CGEN) have trended somewhat positive on Sunday, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Compugen earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 48.0647508470854 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- Active Daily Watch List: Compugen Ltd. (CGEN), Leading Brands, Inc. (LBIX) (newsregistrar.com)
- Form 6-K COMPUGEN LTD For: Aug 07 (streetinsider.com)
- Q3 2018 EPS Estimates for Compugen Ltd. (CGEN) Lowered by Analyst (americanbankingnews.com)
- Jefferies Financial Group Equities Analysts Boost Earnings Estimates for Compugen Ltd. (CGEN) (americanbankingnews.com)
Shares of NASDAQ CGEN traded up $0.05 during mid-day trading on Friday, reaching $3.05. 61,733 shares of the company traded hands, compared to its average volume of 135,750. The firm has a market cap of $153.88 million, a price-to-earnings ratio of -4.24 and a beta of 0.27. Compugen has a fifty-two week low of $2.25 and a fifty-two week high of $5.00.
CGEN has been the topic of a number of analyst reports. ValuEngine lowered Compugen from a “hold” rating to a “sell” rating in a report on Friday, May 11th. Zacks Investment Research lowered Compugen from a “hold” rating to a “sell” rating in a report on Tuesday, July 10th.
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.